Drugs that contain Finerenone
1. Kerendia patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8436180 | BAYER HLTHCARE | Substituted-4-aryl-1,4-dihydro-1,6-naphthyridinamides and use thereof |
Apr, 2029
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 09, 2026 |
| M(M-279) | Sep 01, 2025 |
NCE-1 date: 09 July, 2025
Market Authorisation Date: 09 July, 2021
Treatment: NA
Dosage: TABLET;ORAL
More Information on Dosage
KERENDIA family patents
